Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...

Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment. On Wednesday, Gilead Sciences, Inc. (GILD) stock ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Genesis Therapeutics, Inc. announced today that the companies have entered into a ...

Parnassus Value Equity Fund stated the following regarding Gilead Sciences, Inc. (NASDAQ:GILD) in its first quarter 2024 investor letter: “Gilead Sciences, Inc. (NASDAQ:GILD), a global ...

today announced that its executive management team will participate in the ATB Capital Markets 2024 Life Sciences Institutional Investor Conference being held on September 18, 2024 in New York City.

today announced that its executive management team will participate in the ATB Capital Markets 2024 Life Sciences Institutional Investor Conference being held on September 18, 2024 in New York City.

PhotonPharma's presentation at the Rocky Mountain Life Sciences Investor and Partnering Conference will provide an overview of the company's progress and development plans. Investors and partners ...